ICER president Steven Pearson at JPM23 (Adrien Villez for Endpoints News)
At $2M per shot, ICER says two new sickle cell gene therapies could be cost-effective
Gene therapies approved by the FDA have so far brought with them eye-popping prices of $2 million or more because of the extraordinary savings, sometimes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.